MX2022001151A - Inhibidores deuterados de la via mk2 y metodos de uso de los mismos. - Google Patents
Inhibidores deuterados de la via mk2 y metodos de uso de los mismos.Info
- Publication number
- MX2022001151A MX2022001151A MX2022001151A MX2022001151A MX2022001151A MX 2022001151 A MX2022001151 A MX 2022001151A MX 2022001151 A MX2022001151 A MX 2022001151A MX 2022001151 A MX2022001151 A MX 2022001151A MX 2022001151 A MX2022001151 A MX 2022001151A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- deuterated
- same
- pathway inhibitors
- map kinase
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente descripción proporciona compuestos deuterados de piridinona-piridinilo y composiciones útiles en el tratamiento de enfermedades mediadas por Cinasa p38 MAP, que tienen las estructuras de la Fórmula (I): (ver Fórmula) en donde los grupos A, B y R son como se define en la descripción detallada. También se proporcionan métodos de inhibición de la actividad de la cinasa MAP p38 en un sujeto humano o animal.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962881026P | 2019-07-31 | 2019-07-31 | |
| PCT/US2020/044558 WO2021022186A1 (en) | 2019-07-31 | 2020-07-31 | Deuterated mk2 pathway inhibitors and methods of using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022001151A true MX2022001151A (es) | 2022-02-22 |
Family
ID=74228512
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022001151A MX2022001151A (es) | 2019-07-31 | 2020-07-31 | Inhibidores deuterados de la via mk2 y metodos de uso de los mismos. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220288070A1 (es) |
| EP (1) | EP4003344A4 (es) |
| JP (1) | JP2022542434A (es) |
| KR (1) | KR20220041180A (es) |
| CN (1) | CN114206339A (es) |
| AU (1) | AU2020319879A1 (es) |
| BR (1) | BR112022001324A2 (es) |
| CA (1) | CA3149304A1 (es) |
| IL (1) | IL290045A (es) |
| MX (1) | MX2022001151A (es) |
| WO (1) | WO2021022186A1 (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2022011748A (es) * | 2020-03-27 | 2022-12-02 | Aclaris Therapeutics Inc | Composiciones orales de inhibidor de ruta de mk2 para el tratamiento de condiciones inmunitarias. |
| EP4313970A1 (en) | 2021-03-31 | 2024-02-07 | Xinthera, Inc. | Mk2 inhibitors and uses thereof |
| US11685719B2 (en) | 2021-07-09 | 2023-06-27 | Xinthera, Inc. | Pyridinone MK2 inhibitors and uses thereof |
| WO2023001282A1 (zh) * | 2021-07-23 | 2023-01-26 | 南京明德新药研发有限公司 | 杂环取代的嘧啶衍生物 |
| WO2023125707A1 (zh) * | 2021-12-29 | 2023-07-06 | 上海美悦生物科技发展有限公司 | 一种p38 MAPK/MK2通路调节剂及其组合物、制备方法和用途 |
| WO2023134765A1 (zh) * | 2022-01-14 | 2023-07-20 | 上海翰森生物医药科技有限公司 | 含五元环类衍生物、其制备方法和应用 |
| WO2023134764A1 (zh) * | 2022-01-14 | 2023-07-20 | 上海翰森生物医药科技有限公司 | 含吡啶多环类衍生物、其制备方法和应用 |
| WO2023150709A2 (en) * | 2022-02-04 | 2023-08-10 | Aclaris Therapeutics, Inc. | Methods of synthesizing deuterated substituted pyridinone-pyridinyl compounds |
| WO2023165554A1 (zh) * | 2022-03-03 | 2023-09-07 | 深圳信立泰药业股份有限公司 | 一种氘代三联吡啶二酮化合物或其盐及其制备方法与应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5466759B2 (ja) * | 2009-05-28 | 2014-04-09 | ノバルティス アーゲー | ネプリライシン阻害剤としての置換アミノ酪酸誘導体 |
| US9359300B2 (en) * | 2010-12-06 | 2016-06-07 | Confluence Life Sciences, Inc. | Methyl/difluorophenyl-methoxy substituted pyridinone-pyridinyl compounds, methyl-pyridinyl-methoxy substituted pyridinone-pyridinyl compounds, and methyl-pyrimidinyl-methoxy substituted pyridinone-pyridinyl compounds |
| DK2648516T3 (da) * | 2010-12-06 | 2019-01-02 | Aclaris Therapeutics Inc | Substituerede pyridinon-pyridinylforbindelser |
| PT3003039T (pt) | 2013-06-07 | 2021-03-04 | Aclaris Therapeutics Inc | Compostos piridinona-piridinilo substituídos com metil/fluoro-piridinil-metoxilo e compostos piridinona-pirimidinilo substituídos com fluoro-pirimidinil-metoxilo |
| AU2017250086A1 (en) * | 2016-04-11 | 2018-09-20 | Clexio Biosciences Ltd. | Deuterated ketamine derivatives |
| AU2018380132B2 (en) * | 2017-12-06 | 2023-11-09 | Lin Bioscience, Inc. | Tubulin inhibitors |
-
2020
- 2020-07-31 BR BR112022001324A patent/BR112022001324A2/pt unknown
- 2020-07-31 CN CN202080051376.9A patent/CN114206339A/zh active Pending
- 2020-07-31 AU AU2020319879A patent/AU2020319879A1/en active Pending
- 2020-07-31 KR KR1020227006713A patent/KR20220041180A/ko unknown
- 2020-07-31 CA CA3149304A patent/CA3149304A1/en active Pending
- 2020-07-31 JP JP2022506384A patent/JP2022542434A/ja active Pending
- 2020-07-31 US US17/630,414 patent/US20220288070A1/en active Pending
- 2020-07-31 WO PCT/US2020/044558 patent/WO2021022186A1/en unknown
- 2020-07-31 EP EP20847487.4A patent/EP4003344A4/en active Pending
- 2020-07-31 MX MX2022001151A patent/MX2022001151A/es unknown
-
2022
- 2022-01-23 IL IL290045A patent/IL290045A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020319879A1 (en) | 2022-02-03 |
| KR20220041180A (ko) | 2022-03-31 |
| BR112022001324A2 (pt) | 2022-03-22 |
| CN114206339A (zh) | 2022-03-18 |
| EP4003344A1 (en) | 2022-06-01 |
| CA3149304A1 (en) | 2021-02-04 |
| JP2022542434A (ja) | 2022-10-03 |
| WO2021022186A1 (en) | 2021-02-04 |
| EP4003344A4 (en) | 2023-07-26 |
| US20220288070A1 (en) | 2022-09-15 |
| IL290045A (en) | 2022-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022001151A (es) | Inhibidores deuterados de la via mk2 y metodos de uso de los mismos. | |
| PH12021550187A1 (en) | Pyrrolopyrimidine itk inhibitors | |
| MY196582A (en) | PD-1/PD-L1 Inhibitors | |
| MX2023004923A (es) | Compuestos heterociclicos como inmunomoduladores. | |
| MX2022000711A (es) | Inhibidores de parp1. | |
| WO2016118951A3 (en) | Heterocyclic itk inhibitors for treating inflammation and cancer | |
| EP4026835A3 (en) | Pd-1/pd-l1 inhibitors | |
| EA201792214A1 (ru) | Соединения замещенного хиназолина | |
| PH12015501868A1 (en) | Inhibitors of histone demethylases | |
| MD3442972T2 (ro) | Inhibitori ai bromodomeniului | |
| TR200102020T2 (tr) | Raf kinaz inhibitörleri olarak w-karboksiaril sübstitüe edilmiş difenil üreler. | |
| MD4800C1 (ro) | Compuşi de aminopirimidinil ca inhibitori de JAK | |
| PH12021550382A1 (en) | Tetrahydropyridopyrimidine derivatives as ahr modulators | |
| PL417066A1 (pl) | Inhibitory arginazy oraz ich zastosowania terapeutyczne | |
| EA200600689A1 (ru) | Замещённые бензазолы и их применение в качестве ингибиторов raf киназы | |
| DK1758860T3 (da) | Mættede og umættede 3-pyridylbenzocykloalkylmethylaminer til behandling af smerter, depressioner og angsttilstande | |
| AU2024202525A1 (en) | Benzimidazolone derived inhibitors of BCL6 | |
| ZA201904522B (en) | Heterocyclic inhibitors of mct4 | |
| MX2022001004A (es) | Inhibidores de enzimas. | |
| TW201625535A (en) | Inhibitors of histone demethylases | |
| MX2021006619A (es) | Inhibidores de la tirosina quinasa, composiciones y sus metodos. | |
| MX2021012501A (es) | Inhibidores de complejo represivo polycomb 2 (prc2). | |
| JOP20220107A1 (ar) | مثبطات egfr تفارغية وطرق استخدامها | |
| MX2017009600A (es) | Derivados de 2-fenil-3h-imidazo[4,5-b]piridina utiles como inhibidores de actividad de receptor huerfano similar a tirosina cinasa (ror1) de tirosina cinasa de mamifero. | |
| MX2022002069A (es) | Inhibidores de enzimas. |